Gluten Intolerance Treatment Market Trends

  • Report ID: 5081
  • Published Date: Dec 20, 2024
  • Report Format: PDF, PPT

Gluten Intolerance Treatment Sector: Growth Drivers and Challenges

Growth Drivers

  • Growing Prevalence of Autoimmune, Allergic, and Non-autoimmune-allergic GRDs – such as dermatitis herpetiformis (DH), celiac diseases, gluten ataxia (GA), wheat allergy (WA), and non-celiac gluten sensitivity (NCGS). As per some studies potentially over 41% of all people with ataxia of unknown origin may have gluten ataxia.

  • Rising Damage of Gut Flora or Dysbiosis – owing to the high usage of antibiotics or consuming food that they can’t digest. Gluten which is a protein is commonly found in wheat, barley, and other grains. Their increasing presence in a lot of processed foods and drinks, including pasta, cereal, and beer, and in things like vitamins, cosmetics, and even certain medications is responsible for the widespread gluten intolerance nowadays. In the United States, nearly 6% of the population is gluten intolerant.

  • Increasing Research & Development – an international research team from Italy and France uncovered a new molecular player in the development of gluten intolerance. The discovery that is published in The EMBO Journal, suggests potential targets for the development of therapeutic approaches for the disease.

Challenges

  • Challenge Associated with Diagnosis – the same clinical manifestations for different GRDs that have specific pathophysiological responses to the ingestion of gluten can make their differential diagnosis challenging which is considered a major factor affecting the market growth.

  • Lack of Awareness

  • Need for Customized Treatment

Base Year

2024

Forecast Year

2025-2037

CAGR

13.8%

Base Year Market Size (2024)

USD 842.52 million

Forecast Year Market Size (2037)

USD 4.52 billion

Regional Scope

  • North America (U.S., and Canada)
  • Asia Pacific (Japan, China, India, Indonesia, Malaysia, Australia, South Korea, Rest of Asia Pacific)
  • Europe (UK, Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Latin America (Mexico, Argentina, Brazil, Rest of Latin America)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)

Browse key industry insights with market data tables & charts from the report:

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of gluten intolerance treatment is assessed at USD 1.03 billion.

The gluten intolerance treatment market size was over USD 842.52 million in 2024 and is projected to reach USD 4.52 billion by 2037, witnessing around 13.8% CAGR during the forecast period i.e., between 2025-2037. The growing prevalence of autoimmune, allergic, and non-autoimmune-allergic GRDs and the rising damage of gut flora will boost the market growth.

Europe industry is predicted to dominate majority revenue share of 34% by 2037, due to increasing review of the broad spectrum of gluten-related disorders, with focused clinical investigations, diagnostic criteria, and therapeutic approaches for different conditions causing gluten intolerance.

The major players in the market are Takeda Pharmaceutical Company Limited, ActoBio Therapeutics, Inc., Precigen, Inc., Calypso Biotech BV, ImmunogenX, Inc., Alvine Pharmaceuticals, Dr. Falk Pharma GmbH, ImmusanT, Inc., Zedira GmbH, FunZyme BioTechnologies S.A., Amyra Biotech AG
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos